GBIO Logo

Generation Bio Co. (GBIO) 

NASDAQ$0.48
Market Cap
$32.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
238 of 924
Rank in Industry
136 of 527

GBIO Insider Trading Activity

GBIO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$203,209267
Sells
$18,410133

Related Transactions

Quinn Anthony G.director2$203,2090$0$203,209
Paone AntoinetteCHIEF OPERATING OFFICER0$01$18,410$-18,410

About Generation Bio Co.

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Insider Activity of Generation Bio Co.

Over the last 12 months, insiders at Generation Bio Co. have bought $203,209 and sold $18,410 worth of Generation Bio Co. stock.

On average, over the past 5 years, insiders at Generation Bio Co. have bought $34.8M and sold $14.74M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Quinn Anthony G. (director) — $203,209.

The last purchase of 85,000 shares for transaction amount of $82,450 was made by Quinn Anthony G. (director) on 2025‑01‑13.

List of Insider Buy and Sell Transactions, Generation Bio Co.

2025-01-13PurchaseQuinn Anthony G.director
85,000
0.1322%
$0.97$82,450-25.71%
2025-01-10PurchaseQuinn Anthony G.director
125,791
0.1948%
$0.96$120,759-25.78%
2024-07-01SalePaone AntoinetteCHIEF OPERATING OFFICER
6,719
0.0099%
$2.74$18,410-15.37%
2024-01-02SaleSamayoa PhillipCHIEF STRATEGY OFFICER
2,445
0.0032%
$1.62$3,961+34.14%
2024-01-02SalePaone AntoinetteCHIEF OPERATING OFFICER
2,445
0.0032%
$1.62$3,961+34.14%
2023-12-08PurchaseAppelhans Dannielledirector
8,000
0.0127%
$1.79$14,339+46.49%
2023-12-04PurchaseRowland Charles A Jrdirector
150,000
0.2255%
$1.50$225,000+65.23%
2023-12-04PurchaseAppelhans Dannielledirector
12,000
0.018%
$1.50$18,000+65.23%
2023-12-01PurchaseRowland Charles A Jrdirector
192,960
0.2723%
$1.31$252,778+80.22%
2023-12-01PurchaseNicholson Donald Williamdirector
100,000
0.1551%
$1.44$144,000+80.22%
2023-12-01PurchaseQuinn Anthony G.director
88,495
0.1344%
$1.41$124,778+80.22%
2023-08-23SalePaone AntoinetteCHIEF OPERATING OFFICER
3,116
0.0046%
$4.93$15,362-44.22%
2023-07-03SaleSamayoa PhillipCHIEF STRATEGY OFFICER
3,116
0.0054%
$5.29$16,484-41.19%
2023-04-25SalePaone AntoinetteCHIEF OPERATING OFFICER
2,914
0.0049%
$4.61$13,434-27.77%
2023-01-26SalePaone AntoinetteCHIEF OPERATING OFFICER
2,695
0.0044%
$5.56$14,984-26.23%
2023-01-10SalePaone AntoinetteCHIEF OPERATING OFFICER
1,865
0.003%
$4.57$8,523-8.80%
2023-01-09SaleSamayoa PhillipCHIEF STRATEGY OFFICER
1,865
0.0035%
$5.11$9,530-6.05%
2022-10-27SalePaone AntoinetteCHIEF OPERATING OFFICER
2,914
0.0051%
$5.03$14,657-5.45%
2022-09-29SalePaone AntoinetteCHIEF OPERATING OFFICER
2,828
0.0049%
$5.24$14,819-5.30%
2022-03-09PurchaseNicholson Donald William
8,126
0.0137%
$4.71$38,273+14.72%
Total: 96
*Gray background shows transactions not older than one year

Insider Historical Profitability

47.16%
Quinn Anthony G.director
299286
0.4481%
$143,657.2830+80.22%
Invus Public Equities, L.P.10 percent owner
2814191
4.2133%
$1.35M10+47.36%
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10 percent owner
2112546
3.1628%
$1.01M10+47.36%
Seybold William10 percent owner
1918819
2.8728%
$921,033.1210+47.36%
Zone Healthcare Holdings, LLC10 percent owner
1918819
2.8728%
$921,033.1210+47.36%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$14,315,062
61
-6.21%
$32.26M
$22,186,116
57
-43.73%
$36.64M
$53,490,060
55
19.35%
$29.82M
$23,895,365
34
-37.28%
$36.88M
$1,295,471
17
21.79%
$25.28M

GBIO Institutional Investors: Active Positions

Increased Positions40+48.19%4M+7.28%
Decreased Positions31-37.35%5M-9.81%
New Positions16New3MNew
Sold Out Positions13Sold Out4MSold Out
Total Postitions92+10.84%54M-2.53%

GBIO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Price T Rowe Associates Inc /Md/$5,382.0013.85%9.28M-72,531-0.78%2024-12-31
Atlas Venture Life Science Advisors, Llc$4,802.0012.36%8.28M00%2024-12-31
Fmr Llc$2,683.006.91%4.63M-694,221-13.05%2024-12-31
Blackrock, Inc.$2,006.005.16%3.46M+43,067+1.26%2024-12-31
Bank Of America Corp /De/$1,739.004.47%3M+14,647+0.49%2024-12-31
Siren, L.L.C.$1,730.004.45%2.98M00%2024-12-31
Vanguard Group Inc$1,532.003.94%2.64M+6,274+0.24%2024-12-31
Jefferies Financial Group Inc.$1,312.003.38%2.26M+2MNew2024-12-31
Ecor1 Capital, Llc$1,187.003.06%2.05M00%2024-12-31
Baker Bros. Advisors Lp$1,128.002.9%1.94M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
2.29SellsBuysStrong BuyBuyHoldSellStrong Sell